AU2014334222B2 - Icotinib-containing topical skin pharmaceutical composition and use thereof - Google Patents

Icotinib-containing topical skin pharmaceutical composition and use thereof Download PDF

Info

Publication number
AU2014334222B2
AU2014334222B2 AU2014334222A AU2014334222A AU2014334222B2 AU 2014334222 B2 AU2014334222 B2 AU 2014334222B2 AU 2014334222 A AU2014334222 A AU 2014334222A AU 2014334222 A AU2014334222 A AU 2014334222A AU 2014334222 B2 AU2014334222 B2 AU 2014334222B2
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition according
group
icotinib
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014334222A
Other languages
English (en)
Other versions
AU2014334222A1 (en
Inventor
Shaojing Hu
Yunyan Hu
Yanping Wang
Yinxiang Wang
Shujun YUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Betta Pharmaceuticals Co Ltd
Original Assignee
Betta Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Betta Pharmaceuticals Co Ltd filed Critical Betta Pharmaceuticals Co Ltd
Publication of AU2014334222A1 publication Critical patent/AU2014334222A1/en
Application granted granted Critical
Publication of AU2014334222B2 publication Critical patent/AU2014334222B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2014334222A 2013-10-11 2014-10-11 Icotinib-containing topical skin pharmaceutical composition and use thereof Ceased AU2014334222B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013085042 2013-10-11
CNPCT/CN2013/085042 2013-10-11
PCT/CN2014/088344 WO2015051763A1 (zh) 2013-10-11 2014-10-11 一种含埃克替尼的皮肤外用药物组合物及其应用

Publications (2)

Publication Number Publication Date
AU2014334222A1 AU2014334222A1 (en) 2016-05-05
AU2014334222B2 true AU2014334222B2 (en) 2017-03-09

Family

ID=52812537

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014334222A Ceased AU2014334222B2 (en) 2013-10-11 2014-10-11 Icotinib-containing topical skin pharmaceutical composition and use thereof

Country Status (13)

Country Link
US (2) US20160235757A1 (US20070167479A1-20070719-C00034.png)
EP (1) EP3056206A4 (US20070167479A1-20070719-C00034.png)
JP (1) JP6463745B2 (US20070167479A1-20070719-C00034.png)
AU (1) AU2014334222B2 (US20070167479A1-20070719-C00034.png)
BR (1) BR112016007627A2 (US20070167479A1-20070719-C00034.png)
CA (1) CA2926874C (US20070167479A1-20070719-C00034.png)
HK (1) HK1213813A1 (US20070167479A1-20070719-C00034.png)
IL (1) IL245015A0 (US20070167479A1-20070719-C00034.png)
NZ (1) NZ718802A (US20070167479A1-20070719-C00034.png)
RU (1) RU2698796C2 (US20070167479A1-20070719-C00034.png)
SG (1) SG11201602826VA (US20070167479A1-20070719-C00034.png)
TW (1) TWI630921B (US20070167479A1-20070719-C00034.png)
WO (1) WO2015051763A1 (US20070167479A1-20070719-C00034.png)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201509753SA (en) * 2013-06-09 2015-12-30 Betta Pharmaceuticals Co Ltd New polymorphic forms of icotinib phosphate and uses thereof
WO2022022434A1 (zh) * 2020-07-27 2022-02-03 杭州和正医药有限公司 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
CN116829152A (zh) * 2021-02-02 2023-09-29 贝达药业股份有限公司 埃克替尼在非小细胞肺癌术后辅助治疗中的应用
CN116492293A (zh) * 2022-01-25 2023-07-28 杭州和正医药有限公司 一种含托法替尼的局部用药的药物组合物、制剂及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182882A1 (en) * 2008-07-08 2011-07-28 Beta Pharma, Inc. Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521404A (ja) * 2005-11-24 2009-06-04 ビーエーエスエフ ソシエタス・ヨーロピア ケラチン結合ポリペプチドとカルボキシル基又はスルホン酸基を有するエフェクター分子とのカップリング方法
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
GB201010954D0 (en) * 2010-06-29 2010-08-11 Edko Pazarlama Tanitim Ticaret Compositions
WO2012053007A1 (en) * 2010-10-21 2012-04-26 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110182882A1 (en) * 2008-07-08 2011-07-28 Beta Pharma, Inc. Icotinib Hydrochloride, Synthesis, Crystalline Forms, Pharmaceutical Compositions, and Uses Thereof

Also Published As

Publication number Publication date
TWI630921B (zh) 2018-08-01
IL245015A0 (en) 2016-05-31
CA2926874C (en) 2018-12-11
RU2016118063A (ru) 2017-11-16
EP3056206A4 (en) 2017-07-05
CA2926874A1 (en) 2015-04-16
HK1213813A1 (zh) 2016-07-15
TW201513894A (zh) 2015-04-16
BR112016007627A2 (pt) 2017-08-01
AU2014334222A1 (en) 2016-05-05
US20160235757A1 (en) 2016-08-18
JP6463745B2 (ja) 2019-02-06
NZ718802A (en) 2017-09-29
RU2698796C2 (ru) 2019-08-30
US20190321369A1 (en) 2019-10-24
SG11201602826VA (en) 2016-05-30
WO2015051763A1 (zh) 2015-04-16
JP2016532659A (ja) 2016-10-20
EP3056206A1 (en) 2016-08-17

Similar Documents

Publication Publication Date Title
US20190321369A1 (en) Icotinib-containing topical skin pharmaceutical compositions and use thereof
WO2022022434A1 (zh) 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
US20230255911A1 (en) Compositions of bioactive fulvate fractions and uses thereof
AU2009223158A1 (en) Formulations of vitamin K analogs for topical use
US6538030B2 (en) Treating radiation fibrosis
JP5891651B2 (ja) 角層細胞分化正常化用皮膚外用剤
US9572777B2 (en) Topical pharmaceutical composition comprising nanonized silver sulfadiazine
WO2016108130A1 (en) Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
EP2854784B1 (en) Method for treating skin inflammatory diseases
WO2024125641A1 (zh) 一系列多肽/蛋白质及其应用
CN109172518B (zh) 一种含维生素k1的外用制剂及其制备方法
WO2023077397A1 (en) Use of mangosteen fruit shell extract in the preparation of a medicament for treating psoriasis
WO2019044670A1 (ja) ざ瘡様疾患を治療又は予防するための皮膚外用組成物
KR20160061425A (ko) 이코티닙-함유 국소 피부 약학 조성물 및 이의 용도
CN105101966A (zh) 一种含埃克替尼的皮肤外用药物组合物及其应用
CN112088002A (zh) 治疗皮肤纤维化的组合物和方法
EP1517691B1 (de) Verwendung von dopamin-rezeptor-agonisten zur behandlung von hautgeschwülsten, warzen und narben
WO2021235275A1 (ja) ヒアルロン酸産生促進剤およびコラーゲン産生促進剤
WO2024125500A1 (zh) 一种局部药物组合物及其在医药上的应用
WO2017188843A1 (ru) Лечебно-косметическое средство для профилактики и комплексного лечения дерматозов
WO2019173219A1 (en) Compositions and methods for treating pigmentation disorders
EP2793897B1 (en) Treatment of seborrhoea
ITPD20100090A1 (it) Formulazione topica per il trattamento di eruzioni cutanee, in particolare conseguenti a trattamenti con farmaci anti egfr

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired